Zak Mir talked to Arnab Basu, CEO and Claire Burgess, CFO, as the developer of radiation and bio-detection technology solutions for the advanced imaging and CBRN detection segments, announced its final results for the year ended 30 April 2025. Revenue increased 37% to £26.5m (2024: £19.4m). Adjusted EBITDA increased to £10.3m (2024: £3.1m). Profit before tax was significantly ahead of market expectations at £3.1m (2024: £3.5m loss), which is positive for the first time in the history of Kromek.
